This is an automatically translated article.
Omeprazole is a drug that inhibits gastric acid secretion. This active ingredient is present in many different preparations, including the drug Ompral of Tipharco Pharmaceutical Joint Stock Company. So what is Ompral and how is it indicated?1. What is Ompral?
Ompral medicine contains the main active ingredient Omeprazol (in the form of enteric coated microparticles) with 2 strengths: Ompral 20 and Ompral 40.
Ompral is manufactured and distributed by Tipharco Pharmaceutical Joint Stock Company (Vietnam), prepared in the form of hard capsules containing enteric coated micro-granules and packed in each box of 10 blisters x 10 tablets or 1 bottle of 100 tablets. . Omeprazol in Ompral belongs to the group of specific inhibitors of the Hydrogen-potassium Adenosine Triphosphatase enzyme system (also known as the proton pump) of the parietal cells of the stomach. Ompral drug acts on the last stage of gastric acid secretion, a single dose of Omeprazole 20mg/day rapidly inhibits gastric secretion due to any stimulant.
2. Indications and contraindications of Ompral
Ompral is indicated for the treatment of the following cases:
Gastroesophageal reflux disease (GERD); Gastrointestinal ulcers; Zollinger-Ellison syndrome. However, patients with a predisposition to hypersensitivity to Omeprazole, Esomeprazole or other benzimidazole derivatives (such as Lansoprazole, Pantoprazole or Rabeprazole) and allergy to any of the other ingredients in Ompral should not use this product. This product is contraindicated.
3. Dosage, how to use Ompral
Ompral should be swallowed whole, the patient should not crush or chew it.
Recommended dosage of Ompral drug depends on each disease, specifically as follows:
Treatment of symptoms of indigestion caused by excessive acid secretion: 10 or 20mg (1⁄2 to 1 Ompral 20 tablet) per day. days for a period of 2-4 weeks; Gastroesophageal reflux disease (GERD): The usual dose is 20 mg (1 Ompral 20 tablet) x 1 time / day for 4 weeks, can be extended for 4-8 weeks if the disease is not completely cured. In case of accompanying persistent esophagitis, a dose of 40mg/day (1 Ompral 40 tablet) can be used, then maintenance (cured esophagitis) 1 Ompral 20 x 1 tablet once/day; Treatment of peptic ulcers: The usual dose is 1 Ompral 20 tablet per day or 1 Ompral 40 tablet in case of severe ulcers. Duration of treatment is 4 weeks with duodenal ulcer and 8 weeks with gastric ulcer; The regimen for eradicating Helicobacter pylori causing peptic ulcers requires the combination of Ompral with suitable antibiotics in a 2- or 3-drug therapy; Treatment of gastric ulcers caused by non-steroidal anti-inflammatory drugs: 20mg/day (equivalent to 1 tablet of Ompral 20); Zollinger-Ellison syndrome: 60mg x 1 time/day (equivalent to 1.5 Ompral 40 tablets), then adjust the dose as needed. Most patients can effectively control symptoms at doses ranging from 20-120 mg/day, but some patients need to take high doses up to 120 mg (3 Ompral 40 tablets) x 3 times/day; Patients with impaired renal function : No dose adjustment of Ompral is required ; Patients with hepatic impairment: Recommended dosage 10-20mg/day; Elderly (> 65 years old): No dose adjustment of Ompral is required; Children: There is limited experience in the treatment of Ompral in children.
4. Side effects of the drug Ompral
Some common side effects of Ompral:
Headache, drowsiness or dizziness; Nausea, vomiting, abdominal pain, diarrhea, constipation or bloating. The less common side effects of the drug Ompral :
Insomnia; Confusion, fatigue; Urticaria, itching, skin rash; Increased recovery of liver enzymes). Some rare side effects of Ompral:
Sweating, peripheral edema; Hypersensitivity symptoms such as angioedema, fever and anaphylaxis; Decreased white blood cell count, thrombocytopenia , decreased total blood cells or agranulocytosis; Agitation, depression, hallucinations in elderly patients; Hearing disorders; gynecomastia in men; Candida infection, dry mouth; Jaundice or non-jaundice hepatitis; Hepatic encephalopathy ; Bronchospasm; Joint pain, muscle pain; Interstitial nephritis.
5. Notes when using Ompral
During the use of Ompral, patients should pay attention to the following issues:
Patients with symptoms such as weight loss, prolonged vomiting, difficulty swallowing, vomiting blood or black stools ... and suspected or present symptoms of peptic ulcer should be diagnosed to exclude malignancy before taking Ompral, because treatment may obscure symptoms, thereby leading to a diagnosis. late guess. The combination of proton pump inhibitors (such as Ompral) and Atazanavir is not recommended. If a combination of two drugs is required, the patient should be closely monitored for clinical abnormalities. As with other inhibitors of gastric acid secretion, Ompral may reduce the absorption of vitamin B12 (or Cyanocobalamin) due to a decrease or lack of hydrochloric acid. Therefore, this factor should be considered in patients with impaired B12 stores or at risk of reduced vitamin B12 absorption if treated with Ompral for a long time. Omeprazole is an inhibitor of CYP2C19, therefore, when starting or ending treatment with Ompral, the risk of interactions with drugs metabolised by CYP2C19 should be taken into account. When monitoring drug interactions between Clopidogrel and Omeprazole, the clinical correlation of this interaction is not clear, but as a precaution, the concomitant use of Clopidogrel and Ompral is not recommended. Severe hypomagnesaemia has been reported with some patients treated with proton pump inhibitors (eg, Ompral) for at least 3 months and in most cases for about 1 year. Symptoms of severe hypomagnesaemia include fatigue, muscle cramps, delirium, convulsions, dizziness and ventricular arrhythmias... However, most of the symptoms are insidious and go unnoticed. In the majority of patients with hypomagnesaemia, the condition improves after magnesium supplementation and discontinuation of proton pump inhibitors. Patients should have their blood magnesium levels checked prior to initiating therapy and periodically during Ompral therapy if they are on long-term treatment or require concomitant treatment with Digoxin or other hypomagnesaemic agents. Ompral use, especially when taken in high doses and for a long time (more than 1 year), may slightly increase the risk of hip, wrist, and spine fractures. This condition mainly occurs in people who are elderly or have other risk factors. Experimental studies have shown that Omeprazole is not capable of causing malformations and toxicity to the fetus, however, Ompral should not be used in pregnant patients, especially in the first 3 months. This product is also not recommended for use during breastfeeding. Ompral medicine contains the main active ingredient Omeprazole, so it is indicated in the treatment of a number of gastrointestinal diseases. To ensure the effectiveness of treatment and avoid unwanted side effects, patients need to strictly follow the instructions of the doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
